BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39

Benzinga Newsdesk www.benzinga.com Positive 85.4%

Neg 0% Neu 0% Pos 85.4%

BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $28 to $39.